GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EQRx Inc (NAS:EQRX) » Definitions » Net Cash per Share

EQRx (EQRX) Net Cash per Share : $2.36 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EQRx Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). EQRx's Net Cash per Share for the quarter that ended in Sep. 2023 was $2.36.

The historical rank and industry rank for EQRx's Net Cash per Share or its related term are showing as below:

EQRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.74   Med: 1.12   Max: 2.19
Current: 0.99

During the past 4 years, the highest Price-to-Net-Cash Ratio of EQRx was 2.19. The lowest was 0.74. And the median was 1.12.

EQRX's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 3.87 vs EQRX: 0.99

EQRx Net Cash per Share Historical Data

The historical data trend for EQRx's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQRx Net Cash per Share Chart

EQRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Cash per Share
- 1.51 3.12 2.79

EQRx Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.79 2.61 2.48 2.36

Competitive Comparison of EQRx's Net Cash per Share

For the Biotechnology subindustry, EQRx's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQRx's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EQRx's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where EQRx's Price-to-Net-Cash falls into.



EQRx Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

EQRx's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1399.286-66.154-0)/478.674
=2.79

EQRx's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

Net Cash per Share (Q: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1212.3-69.37-0)/484.966
=2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EQRx  (NAS:EQRX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


EQRx Net Cash per Share Related Terms

Thank you for viewing the detailed overview of EQRx's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EQRx (EQRX) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, Cambridge, MA, USA, 02139
EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.
Executives
Dina Ciarimboli officer: General Counsel and Secretary EQRX, INC., 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Clive Meanwell director THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Andreessen Horowitz Lsv Fund I-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Bio Ii, L.l.c. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Lsv Ii, L.l.c. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-q, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-b, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Krishna Yeshwant director C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Kathryn E Giusti director 1499 POST ROAD, FAIRFIELD CT 06824
Melanie Nallicheri director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Ah Bio Fund Iii, L.p. 10 percent owner 2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025